Stock Market News

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

wcc wcc
Apr 27, 2026 - 13:01
0 1
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.

Previous Article

Wall Street expects solid Q1 results for GM, as Ford and Stellantis try to ga...

Next Article

Google warns malicious web pages are poisoning AI agents

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Wow Wow 0
Sad Sad 0
Angry Angry 0
wcc
wcc

Related Posts

The Vanguard Total Stock Market ETF (VTI) Now Holds 18,738,438 Shares of SpaceX Stock. Here's What That Means for Investors.

The Vanguard Total Stock Market ETF (VTI) Now Holds ...

wcc
Jul 28, 2026
0
1
These 4 Earnings Reports Expose the Market’s Growing Economic Divide

These 4 Earnings Reports Expose the Market’s Growing...

wcc
Jul 28, 2026
0
1

Jim Cramer warns AI's circular financing frenzy echo...

wcc
Jul 27, 2026
0
1

CNBC's The China Connection newsletter: A U.S.-China...

wcc
Jul 28, 2026
0
1

SpaceX has now lost the equivalent of a full Tesla i...

wcc
Jul 27, 2026
0
1
Mark Zuckerberg's Meta Is Also One of CoreWeave's Biggest Customers, in a Deal Worth $35 Billion Through 2032. That Didn't Stop CoreWeave Shares From Sinking on Meta's Own Cloud News.

Mark Zuckerberg's Meta Is Also One of CoreWeave's Bi...

wcc
Jul 28, 2026
0
1

Comments (0)

User